Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 13.74B P/E 41.42 EPS this Y -16.20% Ern Qtrly Grth -
Income 1.13B Forward P/E 7.90 EPS next Y 9.80% 50D Avg Chg -3.00%
Sales 2.35B PEG 2.36 EPS past 5Y 41.67% 200D Avg Chg -16.00%
Dividend 2.00% Price/Book 2.31 EPS next 5Y 3.20% 52W High Chg -31.00%
Recommedations 1.90 Quick Ratio 7.87 Shares Outstanding 450.98M 52W Low Chg 5.00%
Insider Own 3.79% ROA 5.62% Shares Float 384.42M Beta 0.45
Inst Own 71.82% ROE 17.34% Shares Shorted/Prior 14.15M/12.65M Price 30.65
Gross Margin 76.19% Profit Margin 48.20% Avg. Volume 2,432,067 Target Price 45.50
Oper. Margin 102.82% Earnings Date May 9 Volume 1,837,290 Change -0.81%
About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc News
05/04/24 Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21
04/20/24 Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
04/19/24 Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
04/17/24 Royalty Pharma Declares Second Quarter 2024 Dividend
03/30/24 Royalty Pharma plc's (NASDAQ:RPRX) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
02/28/24 Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
02/18/24 Analysts Have Made A Financial Statement On Royalty Pharma plc's (NASDAQ:RPRX) Yearly Report
02/17/24 Royalty Pharma Full Year 2023 Earnings: EPS: US$2.54 (vs US$0.098 in FY 2022)
02/16/24 Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
02/15/24 Royalty Pharma PLC (RPRX) Earnings Report: A Detailed Analysis
02/15/24 Royalty Pharma Reports Q4 and Full Year 2023 Results
01/30/24 Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
01/22/24 Royalty Pharma (NASDAQ:RPRX) Is Paying Out A Larger Dividend Than Last Year
01/19/24 Royalty Pharma Announces Dividend Increase
01/08/24 Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
11/27/23 Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
11/26/23 Royalty Pharma plc (NASDAQ:RPRX) is a favorite amongst institutional investors who own 69%
11/13/23 Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
11/13/23 Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
11/09/23 The Royalty Pharma PLC (RPRX) Company: A Short SWOT Analysis
RPRX Chatroom

User Image UncleStock Posted - 1 day ago

$RPRX $ZTS $JNJ $VTRS suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image Iwillbuy Posted - 1 day ago

$RPRX again afterhours games going on here! They don’t want anyone to add to this one!

User Image Iwillbuy Posted - 4 days ago

$RPRX it’s so bad here, but they raise the price up afterhours so no one will buy shares, then they short it down and buy them all back up! This only means this stock is worth a huge amount!

User Image DameWave Posted - 4 days ago

$FBIO Another peer to Fortress Biotech, $RPRX and DRI Healthcare Trust is, as I understand it, Ligand Pharmaceuticals $LGND (haven't had time to check them): https://investor.ligand.com/files/doc_financials/2023/q4/02/Q4-2024-Earnings-Release-Slides_Final-v2-2-27-24.pdf $XBI

User Image DameWave Posted - 4 days ago

$FBIO Another peer to FBIO and $RPRX for royalties in healthcare is DRI Healthcare Trust $DHTRF from Canada which today has a portfolio of 20 products that generate 26 different royalty revenues and a market cap of about $700 M, which is over 20 times higher than FBIO's potential future royalty's portfolio consisting of 35 products today. You can read more about DRI Healthcare Trust here: https://drihealthcare.com/wp-content/uploads/2024/04/DRI-Healthcare-Trust-Corporate-Presentation-2024-04-April.pdf $XBI

User Image DameWave Posted - 4 days ago

$FBIO Royalty Pharma $RPRX are early pioneers and have shown the way that you can successfully create great value by acquiring royalties alone. Today the portfolio consists of 48 drugs and over $17 billion in market cap. Fortress Biotech today has a portfolio of 35 (8 commercial and 25 clinical) drugs/products and a market cap of $34 million, and they are the majority owner of most of the companies in the portfolio (see previous post). These brief words do not do Royalty's Pharma and therefore Fortress Biotech's potential justice, to understand this to a greater degree I highly recommend their latest Investor Presentation from February: https://www.royaltypharma.com/wp-content/uploads/2024/02/RPRX-Corporate-Presentation-February-2024.pdf If FBIO manages to 1% achieve what RPRX has in market cap, then they will trade up 5.5 times in the future from current levels. $XBI

User Image DameWave Posted - 4 days ago

$FBIO Fortress Biotech is Royalty Pharma 2.0 Yesterday I wrote about Linc as a comparison to FBIO to demonstrate the latter's extremely low valuation right now. I hope everyone who invested in FBIOs knows that there is also a comparison to look at the future potential of FBIOS royalties in $RPRX. RPRX has a 27-year history, where royalty income started pouring in 13 years ago, with a fine history of being able to earn royalties in some well-known blockbuster drugs. Today the portfolio consists of 48 drugs and a market cap of over $17 Billion (over $35 B at ATH). "2.0" is not a direct comparison, but more to show that although they are similar in many ways, they are also different. RPRX royalties are usually about twice as high in percentage compared to FBIO's average of 4.5%, but then FBIO has almost exclusively a 2.5% annual equity dividend. Above all, the big difference is that FBIO co-owns (often majority owners) their companies and has founded most of them $XBI https://www.royaltypharma.com/our-firm/our-portfolio/

User Image hi_tech_low_life Posted - 5 days ago

Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment $AMGN $ARWR $RPRX https://www.benzinga.com/general/biotech/24/05/38601856/amgen-reports-better-than-expected-q1-results-50m-milestone-payment

User Image Fullratio Posted - 04/22/24

Healthcare sector stocks with high EPS growth in Q4 2023 (TTM): $LIVN $PBYI $RPRX

User Image Stock_Titan Posted - 04/19/24

$RPRX Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 https://www.stocktitan.net/news/RPRX/royalty-pharma-to-announce-first-quarter-2024-financial-results-on-ds45to4m10b6.html

User Image JonG12345 Posted - 04/15/24

Every 3 months $RPRX tell us its FCF per share of their last 12 months. A crucial indicator for the price. If we compare it with the price THIS HAS NO SENSE, the higher the FCF/share the lower the price. F*ck off! data: koyfin

User Image UncleStock Posted - 04/11/24

$RPRX $BMY $ZTS $JNJ suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image ViktorSinclair Posted - 04/09/24

$RPRX why is this stock so shitty?

User Image sa_trader Posted - 1 month ago

$RPRX should see pop today, buying on open

User Image Railbird69 Posted - 1 month ago

$RPRX Last Short Interest was healthy < 4% But this week ? They are shorting the f*ck out of this ~ now below 100 ema & Buyers rush in final hour. 💚 The games they play... Hold on. See Feb 5... Back up 10% the next day. 🚀

User Image regard2WSB Posted - 1 month ago

$RPRX trend line still holding.. higher highs / higher lows.

User Image ViktorSinclair Posted - 1 month ago

$RPRX what a shit company. this stock has done NOTHING but go down in value since IPO. Approaching all time lows again.

User Image Iwillbuy Posted - 1 month ago

$RPRX pushed down on no volume… Buy these stupid dips… Watch what happens afterhours to this price! It is being protected from buying… Price will rise extremely higher afterhours to ward off buyers….

User Image UncleStock Posted - 1 month ago

$RPRX $BMY $ZTS $JNJ suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image selllowbuyhigh_ Posted - 03/28/24

$RPRX rprx 60% margin, 8 fwd pe, growing at 10%, weekly bullish cross, why is the markets giving out such low multiples, what’s the catch ?

User Image Iwillbuy Posted - 03/27/24

$RPRX They own the ask they own the bid! They place the bid to extremely high level afterhours to avoid shares being bought up by their organized shorting. The shorting is not because of below value, instead they are squeezing people to give up to sell… This value is way undervalued for a stock with this much equity and cash! I advise buying their early morning dips and just accumulate for a sudden and quick move up by May… Mark these words to be true….

User Image vu_jade Posted - 03/21/24

$RPRX love this turn around lol ok

User Image Fullratio Posted - 03/20/24

Healthcare sector stocks with high EPS growth in Q4 2023 (TTM): $RPRX $ROIV $SRDX

User Image nhruch Posted - 03/18/24

$AGEN this could be an attractive play for $RPRX. Infuse a few hundred million for a significant royalty percentage, as that's there business. As long as it doesn't step on other investments. Any potential suiter might be waiting to see final trial results.

User Image UncleStock Posted - 03/14/24

$RPRX $BMY $JNJ $ZTS suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image sa_trader Posted - 03/12/24

$RPRX Technicals looking good with selling drying up, should see bounce with golden cross 50 SMA crossing 200 SMA

User Image PatMaGroin Posted - 03/10/24

$RPRX

User Image swingingtech Posted - 2 months ago

$RPRX https://wallstreetwaves.com/notable-two-hundred-day-moving-average-cross-rprx/

User Image sa_trader Posted - 2 months ago

$RPRX Golden cross 50MA crossover 200MA, algos will be going long here...added more

User Image UncleStock Posted - 2 months ago

$RPRX $BMY $PFE $JNJ suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

Analyst Ratings
B of A Securities Buy Apr 12, 24
JP Morgan Overweight Feb 20, 24
Goldman Sachs Buy Feb 20, 24
Morgan Stanley Overweight Nov 9, 23
Morgan Stanley Overweight Oct 11, 23
Morgan Stanley Overweight Aug 9, 23
Morgan Stanley Overweight Jul 11, 23
Morgan Stanley Overweight May 10, 23
Morgan Stanley Overweight Apr 10, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
RIGGS RORY B Director Director Jan 02 Sell 27.95 470,000 13,136,500 20,099 01/04/24
Avara Management Ltd 10% Owner 10% Owner Dec 27 Sell 28.11 251,592 7,072,251 2,543,323 12/29/23
Coyne Terrance P. EVP & CFO EVP & CFO Aug 09 Sell 30.73 75,000 2,304,750 790,000 08/11/23
Coyne Terrance P. EVP & CFO EVP & CFO Jul 12 Sell 31 75,000 2,325,000 865,000 07/14/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Jun 02 Sell 33.63 192,221 6,464,392 30,000 06/06/23
Legorreta Pablo G. CEO, Chairman of the.. CEO, Chairman of the Board May 24 Buy 32.2496 150,000 4,837,440 380,000 05/24/23
RIGGS RORY B Director Director May 22 Sell 32.82 1,750,000 57,435,000 6,762 05/22/23
RIGGS RORY B Director Director Mar 29 Sell 36.6 139,950 5,122,170 1,456,762 03/30/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Mar 28 Sell 37.04 112,779 4,177,334 212,221 03/30/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Feb 23 Sell 37.2663 25,000 931,658 325,000 02/27/23
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Feb 22 Sell 37.2965 23,333 870,239 46,667 02/24/23
RIGGS RORY B Director Director Dec 09 Sell 42.02 60,000 2,521,200 96,712 12/13/22
Coyne Terrance P. EVP & CFO EVP & CFO Nov 02 Sell 43.0629 5,500 236,846 964,500 11/04/22
Giuliani Mario Germano Director Director Sep 28 Sell 41.05 32,593 1,337,943 8,077,140 09/30/22
Giuliani Mario Germano Director Director Sep 22 Sell 41.1681 211,380 8,702,113 8,109,733 09/26/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 20 Sell 41.0201 267,815 10,985,798 21,426,170 09/22/22
Giuliani Mario Germano Director Director Sep 16 Sell 41.61 387,171 16,110,185 22,657,815 09/20/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 16 Sell 41.61 387,171 16,110,185 21,693,985 09/20/22
RIGGS RORY B Director Director Sep 14 Sell 42.31 100,000 4,231,000 276,712 09/15/22
Giuliani Mario Germano Director Director Sep 07 Sell 42.7 499,500 21,328,650 8,577,140 09/09/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 07 Sell 42.7 498,006 21,264,856 22,426,170 09/09/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Aug 25 Sell 44 1,994 87,736 22,924,176 08/29/22
Giuliani Mario Germano Director Director Aug 25 Sell 44 500 22,000 9,076,640 08/29/22
RIGGS RORY B Director Director Aug 09 Sell 43.7294 45,000 1,967,823 376,712 08/11/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Aug 09 Sell 43.92 20,854 915,908 201,114 08/11/22
Coyne Terrance P. EVP & CFO EVP & CFO Aug 01 Sell 43.1909 30,000 1,295,727 970,000 08/03/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jul 28 Sell 43.9676 4,046 177,893 221,968 08/01/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jul 25 Sell 43.28 75,100 3,250,328 226,014 07/27/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Jul 25 Sell 43.12 23,334 1,006,162 07/27/22
RIGGS RORY B Director Director Jun 29 Sell 42.1746 30,000 1,265,238 421,712 06/29/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Jun 24 Sell 43.1875 23,333 1,007,694 23,334 06/24/22
Reddoch James F. EVP & Chief Scientif.. EVP & Chief Scientific Officer Jun 08 Sell 41.559 100,000 4,155,900 920,800 06/10/22
Reddoch James F. EVP & Chief Scientif.. EVP & Chief Scientific Officer May 27 Sell 41.0801 75,000 3,081,008 1,020,800 05/31/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC May 26 Sell 40.49 100,000 4,049,000 430,000 05/31/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC May 23 Sell 40.2677 100,000 4,026,770 530,000 05/25/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments May 16 Sell 39.8507 23,333 929,836 46,667 05/16/22
RIGGS RORY B Director Director Mar 29 Sell 38.5887 60,000 2,315,322 601,712 03/30/22
RIGGS RORY B Director Director Mar 17 Sell 39.33 169,089 6,650,270 03/21/22
Fernandez Henry A Director Director Feb 24 Buy 37.4884 32,500 1,218,373 58,200 02/25/22
RIGGS RORY B Director Director Dec 28 Sell 40.16 184,448 7,407,432 592,748 12/30/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Nov 16 Sell 42.51 250,000 10,627,500 630,000 11/18/21
RIGGS RORY B Director Director Nov 16 Sell 42.28 214,389 9,064,367 1,115,645 11/18/21
RIGGS RORY B Director Director Jun 29 Sell 42.17 1,314,912 55,449,839 3,451,258 06/29/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jun 14 Sell 46.47 70,000 3,252,900 240,000 06/14/21
Urist Marshall EVP & Co-Head of R&I EVP & Co-Head of R&I Jun 08 Sell 46.08 33,134 1,526,815 06/08/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jun 04 Sell 42.11 62,500 2,631,875 1,050,000 06/04/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Apr 16 Sell 42.13 69,822 2,941,601 200,000 04/16/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Apr 14 Sell 42.32 449 19,002 255,898 04/14/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Mar 04 Sell 47.37 125,000 5,921,250 300,000 03/04/21
Reddoch James F. EVP, Research & Inve.. EVP, Research & Investments Mar 04 Sell 47.37 100,000 4,737,000 300,000 03/04/21